Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Stock Up 5.2 %

NERV opened at $1.60 on Friday. The firm has a market cap of $11.19 million, a PE ratio of -3.64 and a beta of -0.09. The business has a fifty day simple moving average of $1.66 and a 200-day simple moving average of $2.09. Minerva Neurosciences has a fifty-two week low of $1.15 and a fifty-two week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. On average, equities research analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NERV. Apella Capital LLC purchased a new stake in Minerva Neurosciences in the 1st quarter worth about $35,000. Citadel Advisors LLC increased its holdings in shares of Minerva Neurosciences by 49.5% in the 4th quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 8,525 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Minerva Neurosciences by 60.0% in the fourth quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 13,829 shares in the last quarter. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.